Alvimopan, a selective peripherally acting μ‐opioid antagonist*
- 18 March 2005
- journal article
- review article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 17 (2), 157-165
- https://doi.org/10.1111/j.1365-2982.2005.00640.x
Abstract
Alvimopan is a novel, peripherally acting μ‐opioid antagonist that is being developed for the management of acute postoperative ileus and for the reversal of the delayed gastrointestinal and colonic transit that result in symptoms such as constipation, nausea and motility disorders in patients treated with opiate analgesics. There is a clinical need for effective medications for the treatment of postoperative ileus and opiate‐induced constipation and other motility disorders. This review addresses the basic and applied pharmacology and current evidence for the use of the medication, alvimopan, in clinical gastroenterology.Keywords
This publication has 43 references indexed in Scilit:
- Alvimopan, a Novel, Peripherally Acting μ Opioid AntagonistAnnals of Surgery, 2004
- Clinical perspective on postoperative ileus and the effect of opiatesNeurogastroenterology & Motility, 2004
- Peripheral opiate action on afferent fibres supplying the rat intestineNeurogastroenterology & Motility, 2004
- Preclinical studies of opioids and opioid antagonists on gastrointestinal functionNeurogastroenterology & Motility, 2004
- Opioid-Induced Bowel DysfunctionDrugs, 2003
- Increased tumor necrosis factor-α and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the δ-opioid agonist SNC 80Life Sciences, 2001
- Effect of the opioid antagonist ly 246736 on gastro-intestinal transit in human subjectsGastroenterology, 1998
- Control of muscle tone in the human colon.Gut, 1992
- Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activityDigestive Diseases and Sciences, 1992
- Role of loperamide and placebo in management of irritable bowel syndrome (IBS)Digestive Diseases and Sciences, 1984